Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)
- The report reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chronic Kidney Disease (Chronic Renal Failure) therapeutics and enlists all their major and minor projects
- The report assesses Chronic Kidney Disease (Chronic Renal Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Acahealth Pharma and Biotech Co LtdAdAlta Ltd
Aileron Therapeutics Inc
Alexion Pharmaceuticals Inc
Algernon Pharmaceuticals Inc
Algomedix Inc
Alpha Young LLC
Anagenics Ltd
Angiotensin Therapeutics Inc
Aplagon Oy
Arbormed Co Ltd
Arch Biopartners Inc
Aria Pharmaceuticals Inc
Aronora Inc
Arthrosi Therapeutics Inc
Asahi Kasei Pharma Corp
AstraZeneca Plc
Bayer AG
BerGenBio ASA
Boehringer Ingelheim International GmbH
Byomass Inc
CAMP Therapeutics Inc
Cascade Pharmaceuticals Inc
Ceptur Therapeutics Inc
Certa Therapeutics Pty Ltd
Chinook Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp.
CinCor Pharma Inc
Cinkate Corp
Coegin Pharma AB
CrystalGenomics Inc
CSL Ltd
Daiichi Sankyo Co Ltd
DiaMedica Therapeutics Inc
Dimerix Ltd
DJS Antibodies Ltd
Drug Farm Inc
DURECT Corp
Eagle Pharmaceuticals Inc
EHL Bio Co Ltd
Eli Lilly and Co
Elicio Therapeutics Inc
Ennovabio
Enyo Pharma SA
Evgen Pharma Plc
Evotec SE
Fortress Biotech Inc
Function Therapeutics Inc
Future Medicine Co Ltd
G&P Bioscience Co Ltd
G3 Pharmaceuticals Inc
Galderma SA
Gila Therapeutics Inc
Gmax Biopharm LLC
GNI Group Ltd
Goldilocks Therapeutics Inc
Gubra ApS
Haisco Pharmaceutical Group Co Ltd
Hangzhou Metai Pharmaceutical Technology Co Ltd
Helixmith Co Ltd
Hinova Pharmaceuticals Co Ltd
Hybridize Pharma BV
Icagen Inc
iCELL Biotechnology Co Ltd
Inozyme Pharma Inc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Jikei University School of Medicine
Johnson & Johnson
KBP Biosciences Co Ltd
Keio University
Kibow Biotech Inc
KidneyCure Ltd
Klotho Therapeutics Inc
Leflore Technologies LLC
MabTics
Maze Therapeutics Inc
MD Healthcare Inc
MedAbome Inc
MedBiome Inc
Meridigen Biotech Co Ltd
Mineralys Therapeutics Inc
Mission Therapeutics Ltd
Novartis AG
NovMetaPharma Co Ltd
Novo Nordisk AS
OccuRx Pty Ltd
Oisin Biotechnologies
Oneness Biotech Co Ltd
Opsidio LLC
Orgenesis Inc
OrthoTrophix Inc
Osaka University Hospital
Pharmaxis Ltd
Pharmicell Co Ltd
Poxel SA
Prokidney Corp
Purespring Therapeutics Ltd
RAGE Biotech Pty Ltd
Reata Pharmaceuticals Inc
Redx Pharma Plc
Rege Nephro Co Ltd
Reliance Life Sciences Pvt Ltd
Renibus Therapeutics Inc
Resverlogix Corp
Revelation Biosciences Inc
Saniona AB
Sarfez Pharmaceuticals Inc
Scohia Pharma Inc
Senolytic Therapeutics Inc
Sentien Biotechnologies Inc
Shanghai Pharmaceutical Group Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
siRNAgen Therapeutics Corp
Skye Bioscience Inc
Suzhou Regend Therapeutics Co Ltd
TagCyx Biotechnologies
Two Cells Co Ltd
Unicocell Biomed Co Ltd
Unicycive Therapeutics Inc
Unicyte AG
University of Queensland
Vall d’Hebron Institute of Research
Vascular BioSciences
VCANBIO Cell and Gene Engineering Corp Ltd
Ventus Therapeutics Inc
Vertex Pharmaceuticals Inc
VESSL Therapeutics Ltd
Vidasym Inc
Vivazome Therapeutics Pty Ltd
Vivoryon Therapeutics NV
Walden Biosciences Inc
Wuxi Biocity Biopharma Co Ltd
Zydus Lifesciences Ltd